Profile
Dr. Chris Wahl is a Chief Scientific Officer at Halozyme Therapeutics, Inc. Dr. Wahl was previously employed as a Vice President-Strategy & Business Development by Biora Therapeutics, Inc., a Chief Operating Officer by Interface Therapeutics, Inc., and a Chief Operating Officer by Micropharma Ltd. He received his undergraduate degree from Lee University, an MBA from McGill University and a doctorate degree from McGill University.
Chris Wahl active positions
| Companies | Position | Start |
|---|---|---|
| HALOZYME THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | - |
Former positions of Chris Wahl
| Companies | Position | End |
|---|---|---|
| BIORA THERAPEUTICS, INC. | Corporate Officer/Principal | - |
Interface Therapeutics, Inc. | Founder | - |
Micropharma Ltd.
Micropharma Ltd. Pharmaceuticals: MajorHealth Technology Formulates, manufactures & sells functional food, neutraceuticals and pharmaceutical products | Chief Operating Officer | - |
Training of Chris Wahl
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 6 |
|---|---|
Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc. BiotechnologyHealth Technology Engages in the development and commercialization of recombinant human enzymes for the infertility, ophthalmology & oncology markets | Health Technology |
Micropharma Ltd.
Micropharma Ltd. Pharmaceuticals: MajorHealth Technology Formulates, manufactures & sells functional food, neutraceuticals and pharmaceutical products | Health Technology |
McGill University
McGill University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Lee University
Lee University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Biora Therapeutics, Inc.
Biora Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company focused on developing targeted therapies for cancer and autoimmune diseases | Health Technology |
Interface Therapeutics, Inc. |
- Stock Market
- Insiders
- Chris Wahl
















